Plain-English translation of NCT07656168 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new blood-filtering device called the pHA130 cartridge, used together with standard dialysis, to see if it can better remove harmful waste products that build up when your kidneys fail. Current dialysis is very good at removing some wastes, but not others—particularly sticky toxins that stick to proteins in your blood and contribute to heart disease and itching. This study will compare patients who use the new pHA130 cartridge once a week (along with regular dialysis twice a week) against patients who receive standard dialysis three times a week.
Patients on dialysis often have heart problems and a poor quality of life because current dialysis doesn't remove all the harmful toxins that build up. This new treatment is designed to fill that gap and help reduce these serious complications.
You likely qualify if…
You likely don't qualify if…
After a 4-week observation period, you would be randomly assigned to one of two groups. If assigned to the new treatment group, you would receive dialysis twice a week plus one session per week using the new pHA130 cartridge (12 months total). If assigned to the standard group, you would continue regular dialysis three times a week. Throughout the study, the researchers will measure kidney toxin levels in your blood, assess your quality of life and mental sharpness, check your heart health, and monitor for any side effects.
AI-generated summary from trial data · Jul 8, 2026 · Not medical advice
China